Based on safety, clinical activity, and PK and pharmacodynamic (PD) outcomes, two RP2Ds (1.5 mg intermittently and 1 mg once daily) were selected to inhibit PRMT5 activity in patients with cancerous tumors [133]. The gene discussed is PRMT5; the disease is cancer.